B

Beeline Medicines

Clinical-stage biotech developing precision autoimmune therapies

IT Support Analyst

Full-TimePosted on 10/19/2026
$77k - $100k+ Discretionary annual bonus + Long-term incentive award (equity)
Mid
Bachelor's
Cambridge, MA, USA
In PersonMinimal to occasional travel between office locations or to remote sites may be required.
IT OperationsIT Service Desk & End User Support

About the job

Requirements
  • A Bachelor's degree in Information Technology, Computer Science, or a related discipline, or equivalent years of industry experience.
  • Three years of hands-on IT support experience, including desktop support and end-user troubleshooting.
  • Experience with Microsoft 365 applications and basic administration, including account management.
  • Experience with an ITSM ticketing system such as ServiceNow, Jira Service Management, or an equivalent system.
  • Proficiency troubleshooting Outlook, Teams, OneDrive, and SharePoint at the user level, including account management.
  • Working knowledge of conference room technology and video conferencing, including Teams Rooms.
  • Basic networking knowledge covering Wi-Fi troubleshooting, printer connectivity, VPN, and DNS resolution.
  • Professional, service-oriented presence when working with executives, board members, and external guests.
  • Ability to take ownership of assigned tasks and seek guidance appropriately from senior team members.
  • Reliable follow-through to complete assigned work on time without reminders.
  • Clear documentation habits, including writing accurate ticket notes and following established procedures.
  • Availability during standard business hours, with occasional evening, weekend, or on-call availability for events, system maintenance, upgrades, or urgent issues outside normal hours.
  • Ability to use a computer keyboard and monitor for extended periods; occasionally lift computer equipment, monitors, or peripherals weighing up to 25–50 pounds; and bend, kneel, or reach to install or troubleshoot hardware under desks or in server racks.
Responsibilities
  • Provide first-level and select second-level IT support for office-based employees, troubleshooting and configuring hardware, software, network connectivity, printing, and Microsoft 365 application issues.
  • Resolve tickets within established SLAs, escalate issues beyond scope to the Senior IT Support Analyst, Senior Manager, or MSP service desk, and document support activity in the ITSM ticketing system.
  • Assist the Senior IT Support Analyst in providing priority support to C-suite executives and visiting board members, including workstation setup, device configuration, and pre-meeting technology checks.
  • Serve as the backup on-site technology contact for executive requests as directed.
  • Assist with setup, operation, and breakdown of AV equipment for board presentations, analyst meetings, investor events, and company town halls.
  • Participate in rehearsals, monitor live feeds, and troubleshoot common issues in real time under the direction of senior team members.
  • Perform routine checks and preventive maintenance on conference room technology, including Teams Rooms systems, displays, cameras, microphones, and wireless presentation devices.
  • Set up temporary meeting spaces and support guest Wi-Fi access, loaner devices, and visitor connectivity.
  • Image, configure, and deploy laptops, desktops, and peripherals using standard build processes.
  • Coordinate hardware delivery to end users, maintain accurate endpoint and loaner-device inventory records, and manage office hardware and supplies.
  • Support account provisioning, password resets, MFA troubleshooting, group membership updates, and access requests following established procedures.
  • Perform other duties and responsibilities as assigned.
Desired Qualifications
  • Exposure to Entra ID and Intune.
  • Exposure to conference room systems, video conferencing, or live event/AV support.
  • AV and webcasting experience.
  • Experience in a life sciences, biotech, or pharmaceutical company.

About the company

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million.
  • FDA Fast Track for afimetoran in May 2025 accelerates regulatory interaction.
  • Management plans several clinical starts within 12 months, expanding catalysts beyond lupus.

What critics are saying

  • Afimetoran’s Phase 2 lupus readout in H2 2026 is the company’s make-or-break catalyst.
  • Failure versus Benlysta, Saphnelo, and competing lupus drugs kills the pivotal plan.
  • Five BMS-origin assets concentrate scientific risk; one bad readout can crush financing appetite.

What makes Beeline Medicines unique

  • BMS licensed five programs to Beeline in 2025, de-risking discovery.
  • Afimetoran targets TLR7/8, an upstream lupus mechanism unlike downstream cytokine biologics.
  • Saqib Islam and SpringWorks veterans bring repeatable biotech execution and exit experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Health Insurance
  • Company Equity
  • Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-3%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...